# FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06332092/  
OnCo record `nct06332092` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FID007 in head and neck squamous cell carcinoma, run by Fulgent Pharma LLC., active and no longer recruiting.

## Summary

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06332092 by Fulgent Pharma LLC., with 46 participants enrolled, started 2024-04-10 and due to reach its primary completion in 2025-12-31. Interventions recorded: FID007.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06332092
- Phase: 2
- Setting: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
- Sponsor: Fulgent Pharma LLC.
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06332092: https://clinicaltrials.gov/study/NCT06332092

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)

---
JSON: https://onco.cc/api/v1/entities/nct06332092.json